First Guidance on Use of Controversial Alzheimer's Drug First Guidance on Use of Controversial Alzheimer's Drug
An expert panel provides initial recommendations for the safe and effective use of the controversial anti-amyloid drug aducanumab, as infusions start and clinicians request clarity and advice.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 27, 2021 Category: Internal Medicine Tags: Psychiatry News Source Type: news

Cleaning Up the Air Could Help Prevent Alzheimer ’ s
(Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 26, 2021 Category: Respiratory Medicine Tags: Neurology, Pulmonology, Geriatrics, Preventive Medicine, News, Source Type: news

Cleaning Up the Air Could Help Prevent Alzheimer's
MONDAY, July 26, 2021 -- Air pollution causes you to gasp and wheeze. Smog puts strain on your hearts and inflames your lungs. Could dirty air also be costing you your brain health? A trio of new studies finds that air quality appears linked to a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 26, 2021 Category: General Medicine Source Type: news

Covid vaccines confirmed to cause Parkinson's, dementia symptoms
(Natural News) Former National Institutes of Health (NIH) contract scientist and Classen Immunotherapies proprietor J. Bart Classen has published a paper warning that there is strong potential for Wuhan coronavirus (Covid-19) mRNA “vaccines” to trigger Parkinson’s, dementia and a variety of other prion and chronic diseases. Alzheimer’s, amyotrophic lateral sclerosis (ALS), and multiple system atrophy... (Source: NaturalNews.com)
Source: NaturalNews.com - July 26, 2021 Category: Consumer Health News Source Type: news

New PET tracer detects Alzheimer's disease pathology
A new PET tracer proved for the first time it can be used to identify brai...Read more on AuntMinnie.comRelated Reading: Micro-PET/CT shows long-term Ritalin use safe in ADHD FDG-PET identifies biomarkers in dementia with Lewy bodies Tau PET bests amyloid PET, MRI in Alzheimer's prognostic study New PET tracer effective for imaging early Alzheimer's disease New PET tracer may show early pathology of Alzheimer's disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 26, 2021 Category: Radiology Source Type: news

For Older Adults, Home Care Has Become Harder to Find
Staffing shortages have long plagued the home care industry. But the pandemic has intensified the problem. (Source: NYT Health)
Source: NYT Health - July 24, 2021 Category: Consumer Health News Authors: Paula Span Tags: your-feed-science Home Health Care Layoffs and Job Reductions Labor and Jobs Nursing Homes Elderly Alzheimer ' s Disease Coronavirus (2019-nCoV) Retirement Communities and Assisted Living your-feed-healthcare Source Type: news

Biogen accused of over-marketing controversial new Alzheimer's drug Aduhelm
Biogen is under fire once again because of their controversial Alzheimer's drug, Aduhelm. An online survey published by the company recommends people for a cognitive screening no matter what. (Source: the Mail online | Health)
Source: the Mail online | Health - July 23, 2021 Category: Consumer Health News Source Type: news

Doctors Divided Over Use of Controversial New Alzheimer's Drug
FRIDAY, July 23, 2021 -- The controversial new Alzheimer's drug Aduhelm is creating something of a civil war in medicine, as health networks, hospitals, insurers and individual doctors weigh impending discussions with patients about whether they... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 23, 2021 Category: General Medicine Source Type: news

Health Highlights: July 23, 2021
Here's some of HealthDay's top stories for Friday, July 23: Arguing for& against approval of controversial Alzheimer's drug. The FDA earlier this month gave its OK to the first new Alzheimer's drug in years -- despite its own panel voting 10-1... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 23, 2021 Category: General Medicine Source Type: news

HealthDay Now: Experts Weigh In On Alzheimer's Drug Controversy
... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 23, 2021 Category: General Medicine Source Type: news

Drug Shows Promise in Easing Dementia-Linked Psychosis
Title: Drug Shows Promise in Easing Dementia-Linked PsychosisCategory: Health NewsCreated: 7/23/2021 12:00:00 AMLast Editorial Review: 7/23/2021 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 23, 2021 Category: Geriatrics Source Type: news

Doctors Divided Over Use of Controversial New Alzheimer's Drug
Title: Doctors Divided Over Use of Controversial New Alzheimer's DrugCategory: Health NewsCreated: 7/23/2021 12:00:00 AMLast Editorial Review: 7/23/2021 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 23, 2021 Category: Geriatrics Source Type: news

Biogen research chief says 'misinformation' is cause for controversy surrounding Alzheimer's drug
Biogen R&D chief says that misinformation is at the heart of the controversy surrounding Aduhelm, his companies newly approved Alzheimer's drug. (Source: the Mail online | Health)
Source: the Mail online | Health - July 22, 2021 Category: Consumer Health News Source Type: news

Biogen increases financial guidance despite 25% revenue drop
Biogen Inc. reported a 25% year-over-year revenue drop in its quarterly earnings Thursday, but investors remain bullish. In fact, the Cambridge biotech has upped its financial guidance by at least $200 million, to between $10.65 billion and $10.85 billion, for the 2021 fiscal year, bolstered by its growing multiple sclerosis portfolio and an expected increase of sales of the newly approved Alzheimer's disease drug Aduhelm. Total revenue attributable to Aduhelm in the second quarter of 2021 was $2… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 22, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

End of Alzheimer's? Scientists REVERSE age-related memory loss in mice
SCIENTISTS have successfully reversed age-related memory loss in mice in a potentially groundbreaking discovery in the treatment of Alzheimer's disease. (Source: Daily Express - Health)
Source: Daily Express - Health - July 22, 2021 Category: Consumer Health News Source Type: news

Aducanumab for Alzheimer's disease: expediting approval and delaying science
At the beginning of this month of June, the Food and Drug Administration (FDA) announced its decision to grant marketing authorisation to the monoclonal antibody aducanumab, the first treatment option targeting and affecting the underlying disease process of Alzheimer's disease, according to the press release of the medicines regulatory agency of the USA. What should have been a source of joy and recognition of the success of basic and clinical sciences, however, resulted in a bitter dispute in the scientific community, that ended up in the resignation of three of the experts who had participated in the committee that advi...
Source: Current Awareness Service for Health (CASH) - July 22, 2021 Category: Consumer Health News Source Type: news

1 in 20 Cases of Dementia Occurs in People Under 65
Title: 1 in 20 Cases of Dementia Occurs in People Under 65Category: Health NewsCreated: 7/21/2021 12:00:00 AMLast Editorial Review: 7/22/2021 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 22, 2021 Category: Geriatrics Source Type: news

We Need to Know How Menopause Changes Women ’s Brains
This might turn out to be a crucial window to try to prevent Alzheimer ’s and other chronic diseases that often accompany older age. (Source: NYT Health)
Source: NYT Health - July 21, 2021 Category: Consumer Health News Authors: Kim Tingley Tags: Estrogen Menopause Women and Girls Alzheimer ' s Disease Brain Hormones Elderly Source Type: news

Evidence of sustained benefits of pimavanserin for dementia-related psychosis
(University of Exeter) A new paper published in the New England Journal of Medicine outlines a clinical trial, conducted in 392 people with psychosis associated with Alzheimer's disease, Parkinson's disease, Lewy body, frontotemporal, or vascular dementia. All participants were given pimavanserin for 12 weeks. Those who met a threshold of symptom improvement were then assigned to pimavanserin or placebo for up to 26 weeks. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2021 Category: International Medicine & Public Health Source Type: news

How Aduhelm, an Unproven Alzheimer ’s Drug, Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen ’s Aduhelm, or aducanumab. (Source: NYT Health)
Source: NYT Health - July 20, 2021 Category: Consumer Health News Authors: Pam Belluck, Sheila Kaplan and Rebecca Robbins Tags: Aduhelm (Drug) Alzheimer ' s Disease Food and Drug Administration Drugs (Pharmaceuticals) Labeling and Labels (Product) Clinical Trials Elderly Science and Technology Regulation and Deregulation of Industry Research Brain Biogen Source Type: news

Lifetime exposure to lead linked to greater dementia risk
(Natural News) A study published in the Journal of Alzheimer’s Disease suggests that lead might play a role in the development of dementia. Researchers from the University of Toronto (U of T) reported this after finding a link between lifetime lead exposure and greater dementia risk. In particular, they found that dementia cases decreased as the use of lead... (Source: NaturalNews.com)
Source: NaturalNews.com - July 20, 2021 Category: Consumer Health News Source Type: news

Why Exercise Can Help Prevent Alzheimer ’s
Scientists have known for a long time that exercise is good for the body. In recent years, they are revealing how it is good for the brain, too. (Source: WebMD Health)
Source: WebMD Health - July 20, 2021 Category: Consumer Health News Source Type: news

Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?
TUESDAY, July 20, 2021 -- Women on hormone replacement therapy (HRT) for menopause go on to have a 58% lower risk of Alzheimer's disease and other neurodegenerative conditions, a new study finds. Although the study wasn't designed to prove cause and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2021 Category: General Medicine Source Type: news

How an Unproven Alzheimer ’s Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen ’s Aduhelm, or aducanumab. (Source: NYT Health)
Source: NYT Health - July 20, 2021 Category: Consumer Health News Authors: Pam Belluck, Sheila Kaplan and Rebecca Robbins Tags: Aduhelm (Drug) Alzheimer ' s Disease Food and Drug Administration Drugs (Pharmaceuticals) Labeling and Labels (Product) Clinical Trials Elderly Science and Technology Regulation and Deregulation of Industry Research Brain Biogen Source Type: news

It ’s #NotTooMuchToMask; let’s keep protecting ourselves and each other against the ongoing threat of COVID-19
As the final coronavirus restrictions across England are lifted and the legal requirements to wear a face mask and social distance come to an end, leading healthcare organisations, charities, unions and medical professionals have joined forces to support the public to make sensible choices that can keep themselves and others safe from infection. Launching a new campaign #NotTooMuchToMask, the group, led by the NHS Confederation, alongside a host of other organisations are encouraging everyone to keep protecting themselves and each other from catching or passing on coronavirus at a time when cases are soaring, and hosp...
Source: UNISON Health care news - July 19, 2021 Category: UK Health Authors: Fatima Ayad Tags: Press release Christina McAnea Covid-19 face masks Source Type: news

It ’s #NotTooMuchToMask
As the final coronavirus restrictions across England are lifted and the legal requirements to wear a face mask and social distance come to an end, leading healthcare organisations, charities, unions and medical professionals have joined forces to support the public to make sensible choices that can keep themselves and others safe from infection. Launching a new campaign #NotTooMuchToMask, the group, led by the NHS Confederation, alongside a host of other organisations are encouraging everyone to keep protecting themselves and each other from catching or passing on coronavirus at a time when cases are soaring, and hosp...
Source: UNISON Health and safety news - July 19, 2021 Category: Occupational Health Authors: Fatima Ayad Tags: Press release Christina McAnea Covid-19 face masks Source Type: news

How Long Do People Want to Live?
Title: How Long Do People Want to Live?Category: Health NewsCreated: 7/19/2021 12:00:00 AMLast Editorial Review: 7/19/2021 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 19, 2021 Category: Geriatrics Source Type: news

Chemists found an effective remedy for " aged " brain diseases
(Ural Federal University) Scientists synthesized chemical compounds that can stop the degeneration of neurons in Alzheimer's, Parkinson's, and other severe brain pathologies. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Zero Benefit of Aducanumab for Alzheimer's Disease, Panel Rules Zero Benefit of Aducanumab for Alzheimer's Disease, Panel Rules
An influential independent panel unanimously voted that aducanumab offers no benefit for Alzheimer's, adding to growing skepticism from medical experts about this controversial drug.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 16, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

No Net Benefit of Aducanumab for Alzheimer's Disease, Panel Rules No Net Benefit of Aducanumab for Alzheimer's Disease, Panel Rules
An influential independent panel unanimously voted that aducanumab offers no benefit for Alzheimer's, adding to growing skepticism from medical experts about this controversial drug.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 16, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Koelsch Communities opens $21M memory center in Puyallup
The family-owned company is based in Olympia and owns and operates 36 senior care facilities in eight states. Deer Ridge is now one of a few facilities in Puyallup that accept patients with Alzheimer ’s and other forms of dementia. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 16, 2021 Category: Pharmaceuticals Authors: Shawna De La Rosa Source Type: news

Koelsch Communities opens $21M memory center in Puyallup
The family-owned company is based in Olympia and owns and operates 36 senior care facilities in eight states. Deer Ridge is now one of a few facilities in Puyallup that accept patients with Alzheimer ’s and other forms of dementia. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2021 Category: Biotechnology Authors: Shawna De La Rosa Source Type: news

Health systems move toward offering newly approved Alzheimer's drug
Aduhelm provides the potential, for some people with early Alzheimer ’s symptoms, to at least slow down the progression of the disease. And it comes as a lot of other therapies have failed. But it's not for everyone. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 15, 2021 Category: American Health Authors: Paul J. Gough Source Type: news

Health systems move toward offering newly approved Alzheimer's drug
Aduhelm provides the potential, for some people with early Alzheimer ’s symptoms, to at least slow down the progression of the disease. And it comes as a lot of other therapies have failed. But it's not for everyone. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 15, 2021 Category: Biotechnology Authors: Paul J. Gough Source Type: news

Two Major Health Systems Will Not Administer Controversial Aduhelm
THURSDAY, July 15, 2021 -- Two major U.S. health systems say they will not administer Aduhelm, the controversial new drug for treating Alzheimer disease. The decisions by the Cleveland Clinic and Mount Sinai Health System in New York City are the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2021 Category: Pharmaceuticals Source Type: news

Cleveland Clinic and Mount Sinai say they will not administer controversial Alzheimer's drug
The Cleveland Clinic and Mount Sinai both will not administer Biogen's Aduhelm, they announced this week. The move comes after controversy surrounding the drug's FDA approval. (Source: the Mail online | Health)
Source: the Mail online | Health - July 15, 2021 Category: Consumer Health News Source Type: news

Ohio Clinic Says It Won't Administer Alzheimer's Drug to Patients
The rejection of the new Alzheimer ’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A. (Source: NYT Health)
Source: NYT Health - July 15, 2021 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Drugs (Pharmaceuticals) Aduhelm (Drug) Alzheimer ' s Disease Clinical Trials Elderly Cleveland Clinic Biogen Inc Food and Drug Administration your-feed-healthcare Source Type: news

Two Major Health Systems Won't Administer Controversial New Alzheimer's Drug
THURSDAY, July 15, 2021 -- Two major U.S. health systems say they will not administer the controversial new Alzheimer's drug Aduhelm. The decisions by the Cleveland Clinic and Mount Sinai's Health System in New York City are the latest fallout from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 15, 2021 Category: General Medicine Source Type: news

Reading, Puzzles May Delay Alzheimer's by 5 Years: Study
THURSDAY, July 15, 2021 -- An active mind in old age may delay Alzheimer's disease by up to five years, a new study suggests. Activities like reading, writing letters, playing cards or doing puzzles may prolong brain health even for those in their... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 15, 2021 Category: General Medicine Source Type: news

Two Major Health Systems Won't Administer Controversial New Alzheimer's Drug
Title: Two Major Health Systems Won't Administer Controversial New Alzheimer's DrugCategory: Health NewsCreated: 7/15/2021 12:00:00 AMLast Editorial Review: 7/15/2021 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 15, 2021 Category: Geriatrics Source Type: news

Reading, Puzzles May Delay Alzheimer's by 5 Years: Study
Title: Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyCategory: Health NewsCreated: 7/15/2021 12:00:00 AMLast Editorial Review: 7/15/2021 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 15, 2021 Category: Geriatrics Source Type: news

Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub
MELBOURNE, Australia, July 15, 2021 -- Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product developmen...
Source: Johnson and Johnson - July 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Cleveland Clinic Says It Won ’t Administer Aduhelm to Patients
The major medical center ’s rejection of the new Alzheimer’s drug is one of the starkest signs of concern over its effectiveness. (Source: NYT Health)
Source: NYT Health - July 14, 2021 Category: Consumer Health News Authors: Pam Belluck Tags: your-feed-science Drugs (Pharmaceuticals) Aduhelm (Drug) Alzheimer ' s Disease Clinical Trials Elderly Cleveland Clinic Biogen Inc Food and Drug Administration your-feed-healthcare Source Type: news

Late-Life Cognitive Activity May Delay Dementia
WEDNESDAY, July 14, 2021 -- A cognitively active lifestyle in old age may delay the onset of dementia in Alzheimer disease (AD) by as much as five years, according to a study published online July 14 in Neurology. Robert S. Wilson, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 14, 2021 Category: Pharmaceuticals Source Type: news

Reading and writing letters may delay the onset of Alzheimer's disease by up to five YEARS
A study by researchers at Rush University Medical Center in Chicago asked almost 2,000 older people how long they had spent doing these and similar activities in the previous year. (Source: the Mail online | Health)
Source: the Mail online | Health - July 14, 2021 Category: Consumer Health News Source Type: news

AI-based speech pattern analysis may allow Alzheimer's diagnosis by phone
Patterns of speech in a phone conservation can be used to correctly identify adults in the early stages of Alzheimer's disease, a study published Wednesday by the journal PLOS found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 14, 2021 Category: Consumer Health News Source Type: news

CMS to analyze coverage of monoclonal antibody Alzheimer's drug
The U.S. Centers for Medicare and Medicaid Services (CMS) will conduct a nationa...Read more on AuntMinnie.comRelated Reading: fMRI shows dementia patients' brain response to music New Alzheimer's definition relies on imaging biomarkers DTI-MRI ties lack of fitness to cognitive decline Flortaucipir-PET could lead in early Alzheimer's detection ACR revises Appropriateness Criteria (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 14, 2021 Category: Radiology Source Type: news

Alzheimer's Disease Treatment on the Horizon or False Dawn? Alzheimer's Disease Treatment on the Horizon or False Dawn?
Effective clinical treatment of dementia has eluded us thus far. Dr William Hung comments on the potential for two biologic agents and one modifiable risk factor.Medscape Family Medicine (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - July 14, 2021 Category: Primary Care Tags: Family Medicine/Primary Care Article Source Type: news

Metal-based molecules show promise against the build-up of Alzheimer's peptides
(Imperial College London) In lab tests, Imperial researchers have created a metal-based molecule that inhibits the build-up of a peptide associated with Alzheimer's disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 14, 2021 Category: Biology Source Type: news

Medicare Mulls Coverage for Controversial Drug for Alzheimer Disease
TUESDAY, July 13, 2021 -- Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer disease drug with a high price tag and unproven benefits that have prompted widespread... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 13, 2021 Category: Pharmaceuticals Source Type: news